Merck & Company Inc (MRK)vsSagimet Biosciences Inc. Series A Common Stock (SGMT)
MRK
Merck & Company Inc
$120.60
+0.84%
HEALTHCARE · Cap: $283.78B
SGMT
Sagimet Biosciences Inc. Series A Common Stock
$6.76
-4.25%
HEALTHCARE · Cap: $403.24M
Smart Verdict
WallStSmart Research — data-driven comparison
MRK leads profitability with a 13.6% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 50/100 (D+).
MRK
Hold50
out of 100
Grade: D+
SGMT
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-40.6%
Fair Value
$80.96
Current Price
$120.60
$39.64 premium
Intrinsic value data unavailable for SGMT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : SGMT
The strongest argument for SGMT centers on Debt/Equity, Price/Book.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : SGMT
The primary concerns for SGMT are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
SGMT carries more volatility with a beta of 3.64 — expect wider price swings.
MRK is growing revenue faster at 4.9% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (50/100 vs 21/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Sagimet Biosciences Inc. Series A Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Sagimet Biosciences Inc. (SGMT) is an innovative biotechnology company focused on developing breakthrough treatments for metabolic diseases, particularly non-alcoholic steatohepatitis (NASH). The company is actively advancing its lead therapeutic candidate through various clinical trial phases, employing cutting-edge mechanisms designed to enhance patient outcomes. Backed by a robust management team and a strong intellectual property portfolio, Sagimet is strategically positioned to capitalize on the growing market demand for effective metabolic disease therapies, making it an attractive investment proposition for institutional investors in the dynamic biotech sector.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?